---
layout: default
title: Blinatumomab
parent: 僅模型預測 (L5)
nav_order: 58
evidence_level: L5
indication_count: 0
---

# Blinatumomab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Blinatumomab: Drug Repurposing Evaluation — Insufficient Data to Complete Assessment

## One-Sentence Summary

Blinatumomab (DrugBank ID: DB09052) is a drug with no registered authorizations in Taiwan and no original indication data available in this Evidence Pack.
The TxGNN model returned **no predicted new indications** for this candidate, making a standard repurposing assessment impossible at this stage.
This report documents the current data status and outlines the steps required before evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | None returned by TxGNN |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — Model prediction only (no predictions generated) |
| Germany Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN pipeline could not generate repurposing candidates for Blinatumomab in this run. Two key data gaps are likely responsible:

**Missing mechanism of action (MOA):** TxGNN relies on the drug's known biological targets and pathway annotations to compute similarity scores across disease nodes in the knowledge graph. Without MOA data, the graph traversal cannot find mechanistically plausible disease connections. The DrugBank query was recorded as successful (Query Log ID 3), but the structured MOA field was not returned — this requires a follow-up API call targeting the `drug_interactions` and `mechanism-of-action` endpoints specifically.

**Missing original indication:** The `original_indications` array is empty. Original indication serves as an anchor node in the TxGNN knowledge graph; without it, the model cannot orient its prediction walk. Resolving the Taiwan package insert (Query Log ID 4 was recorded as successful with 1 result, but the content was not parsed into the Evidence Pack) would populate this field.

Until these two gaps are resolved, no scientifically defensible prediction score can be produced.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(No key warnings, contraindications, or drug interaction data were available in this Evidence Pack.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Blinatumomab is missing both a TxGNN prediction and the underlying data (MOA, original indication, safety profile) needed to generate one. Proceeding without this foundation would produce an unreliable evaluation.

**To proceed, the following is needed:**

1. **Parse the Taiwan package insert** — Query Log ID 4 returned 1 result but the content was not ingested. Extract approved indication text, warnings, and contraindications from the PDF.
2. **Retrieve structured MOA from DrugBank** — Query Log ID 3 was successful but the `mechanism-of-action` and `drug-categories` fields are absent. Re-query DrugBank API for DB09052 targeting these specific fields.
3. **Re-run TxGNN pipeline** — Once MOA and original indication are populated, resubmit the candidate to generate ranked disease predictions with scores.
4. **Retrieve DDI data** — The DDI query returned `not_found`; consider querying an alternative source (e.g., DrugBank interactions endpoint or the NLM drug interaction database) as Blinatumomab is a biologic and interactions may be catalogued differently.
5. **Confirm antineoplastic classification** — Once DrugBank categories are retrieved, determine whether the Cytotoxicity section should be included in the final report.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

